INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is an inherited autosomal-dominant disease with a heterogeneous clinical presentation and natural history, and is a frequent cause of sudden cardiac death (SCD) in young people. It is associated with mutations in genes coding for sarcomere proteins. In the literature, debate surrounds the genotype-phenotype correlation of individual mutations concerning establishing a prognosis according to the mutation present, which could help stratify the disease and allow appropriate genetic counselling to families.

In an adult, HCM is defined by a wall thickness ≥15 mm in one or more left ventricular myocardial segments—as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging (CMR) or computed tomography)—that is not explained solely by loading conditions, but there are cases of HCM with thicknesses of less than 15 mm and even cases without hypertrophy, all documented by the presence of disarray in the histopathological study of the heart, given that they are also cases with high arrhythmic risk and therefore SCD.

In children, the diagnosis of HCM requires an LV wall thickness more than two standard deviations greater than the predicted mean (z-score >2, where a z-score is defined as the number of standard deviations from the population mean). Therefore, cases with very little hypertrophy and a lot of fibrosis or disarray do not appear in the clinical guidelines, and there is no reference to their management and prognosis.
Mutations in the troponin T gene ($TNNT2$) were described years ago in several publications with few families, and researchers postulated a high prevalence of SCD in young carriers\textsuperscript{5,6,10,11}, who, in addition, had a phenotype of mild left ventricular hypertrophy\textsuperscript{6,12}.

The first cases were described in 1990 by McKenna et al.\textsuperscript{13}, and the first mutation in $TNNT2$ gene in 1999 by the same group\textsuperscript{14}. Mutations in $TNNT2$ represent around 5\% of cases of HCM. They have been described as associated with moderate or mild hypertrophy with a poor prognosis due to a high risk of SCD, even in the absence of hypertrophy, with early expression in adolescence, based mainly on the study by Watkins et al.\textsuperscript{10}, in which 11 families with 8 different mutations were described.

More recently, two series with a greater number of families have been published\textsuperscript{15,16} (Pasquale et al., 2012, 20 families and 12 mutations, and Ripoll-Vera et al., 2016, 21 families and 6 different mutations) (Table 1). In these last series it was found that

| Studies             | Number of families | Number of patients | Number of cardiac deaths | Number of sudden deaths | Mutation                  |
|---------------------|--------------------|--------------------|--------------------------|-------------------------|--------------------------|
| Watkins\textsuperscript{9} 1995 | 11                 | 112                | 50                       | 39                      | Ile79Asn, Arg92Gln, Phe110Ile, ΔGlu160, Glu163Lys, Glu244Asp, Intron 15 G→A, Arg278Cys |
| Nakajima-Tanaguchi\textsuperscript{22} 1997 | 1                 | 4                  | 2                        | 2                       | Ala104Val, Arg92Trp     |
| Moolman\textsuperscript{11} 1997 | 2                  | 22                 | 7                        | 7                       | Phe110Ile, Arg130Cys, ΔGlu160, Arg92Gln, Arg278Cys |
| Anan\textsuperscript{17} 1998 | 6                  | 18                 | 2                        | 2                       | Phe110Ile, Arg130Cys, ΔGlu160, Arg92Gln, Arg278Cys |
| Torricelli\textsuperscript{18} 2003 | 5                  | 10                 | 0                        | 0                       | Arg92Trp, ΔGlu163, IVS15+1G→A, Ala104Val, Arg278His, Arg92Gln, Arg94Leu, Glu163Lys, Glu83Lys, Ile79Asn |
| Pasquale\textsuperscript{23} 2012 | 20                 | 92                 | ¿?                       | 7                       | Arg278Cys, Arg92Leu, Arg92Trp, ΔGlu163, IVS15+1G→A, Ala104Val, Arg278His, Arg92Gln, Arg94Leu, Glu163Lys, Glu83Lys, Ile79Asn, Arg92Gln, Arg92Trp, Arg286His, Arg278Cys, Arg94His, Ile221Thr |
| Ripoll-Vera 2016     | 21                 | 54                 | 11                       | 6                       | Arg92Gln, Arg92Trp, Arg286His, Arg278Cys, Arg94His, Ile221Thr |
in the \textit{TNNT2} gene HCM up to 19\% the ECG is normal and in 23\% the transthoracic echocardiography (TTE) does not show hypertrophy. On the contrary, up to 24\textendash{}48\% non-sustained ventricular tachycardia is documented. However, we must differentiate which mutations we are talking about. Not all mutations in the \textit{TNNT2} gene have a poor prognosis (Figure 1).

The \textit{Arg92Gln} mutation is the most studied, it can manifest as HCM with little hypertrophy, but also as dilated cardiomyopathy, especially at older ages. The high burden of SCD is a constant in these families. Of 15 cases documented in 10 families, SCD was the first manifestation of the disease in all, at an average age of 21 years (range 11\textendash{}42) and with an average myocardial thickness of 14.6 ± 5.2 mm. Up to 40\% of patients required the implantation of an implantable cardiac defibrillator (ICD), either for primary or secondary prevention. The \textit{Arg94Leu} mutation, like \textit{Arg94Cys} and \textit{Arg94His}, that affect the same residue, also behave with a certain malignancy\textsuperscript{17}. Microscopic evaluation in some studies in carriers of these \textit{TNNT2} mutations indicate that cause less hypertrophy and fibrosis than other sarcomeric mutations, but more disarray. This may be the substrate that explains the high arrhythmic risk\textsuperscript{18}.

Conversely, other mutations such as \textit{Arg278Cys} or \textit{Arg286His}, also in the \textit{TNNT2} gene, have a much more benign course\textsuperscript{16}.

The diagnosis of these patients is therefore complex, and in some cases an ECG and a TTE will not be enough. CMR has shown its usefulness against TTE in the detection of mild hypertrophies or in the evaluation of worst viewed segments by TTE\textsuperscript{19}. Even in those cases with little or no hypertrophy, the presence of late gadolinium enhancement is a risk marker for SCD in these patients. It has been shown that in these cases, where there is an absence of the classic risk factors of SCD in HCM, the presence of more than 15\textendash{}20\% of fibrosis is a strong and independent marker of outcomes. Even Maron et al.\textsuperscript{20} proposed an algorithm in which it is emphasized that a HCM with extensive fibrosis and absence of conventional risk factors of SCD, an ICD should be implanted as primary prevention.

Recently, new techniques have been incorporated in CMR such as T1 mapping and quantification of extracellular volume (ECV), which seem to have a manifest utility as an early marker of the disease, even when fibrosis has not yet appeared (Figure 2).
Figure 2. **Clinical case of a family:** the proband is a 19 years old man with a SCD. His mother had an HCM and is carrier of a mutation in \( TNNT \) gene (\( \text{Arg92Trp} \)). The pedigree shows that there are also 2 sisters and 1 brother carrying the same mutation. Images from the youngest sister are shown: a pathological electrocardiogram with ST elevation in right precordial leads and negatives T waves in lateral and inferior wall, and a TTE and CMR showing a normal LV wall thickness, except for the posterior wall (mild hypertrophy) and a severe amount of fibrosis in this localization (red arrows).

**CONCLUSIONS**

a) The current definition of HCM does not cover all possible phenotypes, because HCM with little or even “no hypertrophy” exists and can have a very bad prognosis, with SCD at young ages, being very frequently the first manifestation of the disease.
b) In histopathology, a lot of disarray is noticeable in this particular phenotype.
c) It is especially related to some mutations in $\text{TNNT2}$. The clinical and prognostic profiles depended greatly on the specific mutation.
d) A common factor is usually the presence of family history of SCD.
e) To stratify the risk of the carriers, we can not trust only the ESC risk score or the classic American criteria.
f) CMR is essential to identify hypertrophy in segments that are more “hidden” to TTE and to evaluate the presence of fibrosis, which is a very important risk marker in these patients and can help us define which patients need an ICD.
g) Investigation of the genotype-phenotype correlation in HCM remains a challenge.
h) Overall, these findings have important implications for the clinical and genetic study of families with cardiomyopathy, above all the findings of some $\text{TNNT2}$ mutations, which, given its demonstrated malignancy, should cause a change in the management of individuals in SCD prevention.

REFERENCES

[1] Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4144 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. *Circulation*. 1995;92:785–9.

[2] Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. *JAMA*. 2006;296:593–601.

[3] Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. *Am J Cardiol*. 1987;60:123–9.

[4] Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. *J Am Coll Cardiol*. 2005;46:1543–50.

[5] Ackerman MJ, VanDriest SL, Ommen SR, Mil, Nishimura RA, Tajik AJ, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. *J Am Coll Cardiol*. 2002;39:2042–8.

[6] Varnava A, Baboonian C, Davison F, De Cruz L, Elliott PM, Davies MJ, et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. *Heart*. 1999;82:621–4.

[7] Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. *Heart*. 2006;92:785–91.

[8] Van Driest SL, Ackerman MJ, Ommen SR, Shaker R, Will ML, Nishimura RA, et al. Prevalence and severity of «benign» mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. *Circulation*. 2002;106:3085–90.

[9] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35(2014):2733–2779.

[10] Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O’Donoghue A, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med*. 1995;332:1058–64.

[11] Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, et al. Sudden death due to troponin T mutations. *J Am Coll Cardiol*. 1997;29:549–55.

[12] Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. *N Engl J Med*. 2000;342:1778–85.

[13] McKenna WJ, Stewart JT, Nihoyannopoulos P, et al. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. *Br Heart J*. 1990;63:287–290.

[14] Varnava A, Baboonian C, Davison F, et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. *Heart*. 1999;82:621–624.

[15] Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna WJ, Elliott P. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. *Circ Cardiovasc Genet*. 2012;5:10–7.

[16] Ripoll-Vera T, Gamez JM, Govea N, et al. Clinical and prognostic profiles of cardiomyopathies caused by mutations in the troponin T gene. *Rev Esp Cardiol*. 2016;69:149–158.
[17] Segura-Villalobos F, Hernandez-Guerra Al, Wangüemert-Perez F, et al. Hypertrophic cardiomyopathy without ventricular hypertrophy: usefulness of genetic and pathological study in preventing sudden death. Rev Esp Cardiol. 2017;70:604–6.

[18] Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5:158–168.

[19] Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E, Ripoll-Vera T, et al. Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms. Rev Esp Cardiol. 2016;69:300–309.

[20] Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. Circulation. 2015;132:292–298.